NCT05119335 2025-11-12
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
Phase 1/2 Terminated
Clinical Trials
5 trialsNCT02174549 2024-11-22
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
Phase 1/2 Recruiting
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT00743379 2015-05-07
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1/2 Completed
NCT01213030 2012-09-25
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Siemens Molecular Imaging
Phase 1/2 Completed